JACKSONVILLE, Fla., Dec. 6, 2016 /PRNewswire/ -- TapImmune, Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease today announced its President and Chief Operating Officer, Dr. John Bonfiglio, will provide a corporate presentation at the LD Micro IX Main Event on Tuesday, December 6, 2016 at 12:00 p.m. (PST). The conference will take place at the Luxe Sunset Boulevard Hotel in Los Angeles.
Dr. Bonfiglio will give an update on the company's progress including the recent uplisting to NASDAQ. He will discuss the company's Phase 2 clinical program in breast and ovarian cancers with its lead vaccine product candidate, TPIV 200, and plans for the second T-cell vaccine candidate, TPIV 110 that will begin trials in 2017. Additionally, he will discuss the preclinical DNA platform technology PolyStart and its potential for amplifying immune responses.
LD Micro Main Event is providing a webcast link to view Dr. Bonfiglio's presentation on December 6, 2016 at 12 p.m. (PST) by CLICKING here.
Conference attendees seeking a one-on-one meeting with Dr. Bonfiglio may contact TapImmune directly, or contact LD Micro IX Main Event.
About TapImmune Inc.
TapImmune Inc. is an immuno-oncology company specializing in the development of innovative technologies for the treatment of cancer, including metastasis, and infectious disease. The Company's peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients' killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company's technologies may be used as stand-alone medications or in combination with current treatment modalities.
Please visit the Company's website at www.tapimmune.com for more details.
Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tapimmune-to-present-at-the-ld-micro-ix-main-event-december-6-8-2016-300373396.html
SOURCE TapImmune, Inc.